Allergen Immunotherapy - Dust Mites, Ragweed & More
Price: FREE for members and non-members
Session recorded on December 7, 2021
Speaker: David Bernstein, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this activity learners should be able to:
1. Review evidence supporting allergen immunotherapy (AIT) for allergic rhinitis due to ragweed and house dust mite
2. Identify important risk benefit considerations when prescribing AIT
3. Discuss the future role of AIT in treating IgE dependent asthma
All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
David Bernstein, MD, Speaker
Disclosures: Speaker: ALK America, GSK; Contracted research: Aimmune, ALK, Amgen, AZ, Boehringer Ingelheim, Genentech, GSK, Leo, Merck, Mylan, Novartis, Novum, Pearl, Regeneron, Shire, Teva
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance